Lipoidal soft hybrid biocarriers in pharmacotherapeutics.

The competition hike in the pharmaceutical market, the reduction in the fresh chemical-entity pipelines of pharmaceutical organization, the unwanted boost up in the cost for developing new chemical entities and the popularity of generics have all contributed to the effort to move ahead with newer drug-delivery systems that are aimed to provide optimized performance. Nanosized lipoidal soft hybrid biocarriers offer promise for safe, effective and targeted pharmacotherapeutics. The possibilities have risen by virtue of their ability of intracellular entry, biocompatible composition, precise control on drug release, targeted drug delivery, compatibility with a wide range of therapeutic compounds and flexibility in their routes of administration. Vesicles are lipoidal soft hybrid biocarrier-based membrane models developed to mimic the biological membrane, making them superior to other carriers by virtue of their biocompatibility and biodegradability. These features of vesicular carriers make them suitable for therapeutic as well as diagnostic applications. The aim of the present compilation is to briefly summarize the applications and developments in vesicular drug delivery through the patents issued in the past decade.